Oral Peptide Shows Long-Term Efficacy in Ulcerative Colitis Trial
An oral peptide targeting the interleukin-23 receptor showed sustained effectiveness in patients with moderate to severe ulcerative colitis, according to a phase IIb trial. The treatment was well tolerated over an extended period.
Patients with ulcerative colitis may benefit from an oral alternative to injectable therapies, based on trial results.
- study
- An oral peptide that blocks the interleukin-23 receptor
- population
- patients with moderately to severely active ulcerative colitis
Taken from the source as published — check the details before acting on them.
Trial design and results
The phase IIb ANTHEM-UC trial evaluated the oral peptide's efficacy and safety in patients with moderately to severely active ulcerative colitis over a long period.
Safety profile
The treatment was associated with a favorable safety profile, with no major adverse events reported during the study period.
Common questions
What is the current status of this treatment?
The treatment is in the phase IIb trial stage, showing long-term efficacy and safety in patients with ulcerative colitis.
Sources
- Oral Peptide Shows Durable Efficacy in Ulcerative Colitis MedPage Today · medpagetoday.com
- Oral IL-23 Inhibitor Shows Long-Term Safety, Efficacy in UC Medscape · medscape.com
Headlines and links belong to the publishers listed above. The summary above is written by The Health Brief; see how this works.
